165MO Trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients (pts) with active brain metastases: Primary outcome analysis from the TUXEDO-1 trialRupert Bartsch, Matthias Preusser, Angelika M. Starzer et al.|Annals of Oncology|2022Cited by 17
187P Stage I results of a phase II study of datopotamab deruxtecan (DATO-DXd) in triple-negative breast cancer (TNBC) patients (pts) with active brain metastases (TUXEDO-2)Rupert Bartsch, Matthias Preusser, Anna S. Berghoff et al.|ESMO Open|2024Cited by 15
Influence of the dramatic fall of HRT prescription on postmenopausal breast cancer incidence: The Austrian DataGeorg Pfeiler, C Singer, Christian Glatz et al.|Senologie - Zeitschrift für Mammadiagnostik und -therapie|2009Cited by 0